Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Largely Avoids Partisan Bloodbath At US Pricing Hearing

Executive Summary

Democrats spent most of their time complaining about Senate Republicans' closed-door process for developing healthcare legislation, leaving little time for the expert witnesses to weigh in on drug pricing.


Related Content

Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says
Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing
Drug Pricing Hearing In Senate Postponed, Handing Innovators Another Victory
Pharma And Intermediaries Split Money Spent On Drugs, Study Shows
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts